Rhythm says RM-718 cut mean BMI 11.6% at Week 16 in Phase 2 trial

Preliminary data in acquired hypothalamic obesity showed seven evaluable patients at 16 weeks, with two mild injection-site hyperpigmentation cases and tolerability broadly in line with the MC4R agonist class.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.